Sales of MS and eczema drugs could top $4bn by 2022
Repatha cuts cardio events, but not mortality.
Peter Guenter, head of Sanofi’s Diabetes & Cardiovascular business, on the future of chronic disease care.
Companies look to take on Pfizer after series of setbacks.
Sales of Praluent can continue during patent case appeal.
Hugo Fry and Dr Hubert Bland take on new roles at Sanofi UK